Aromatase inhibitor: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>David E. Volk
imported>Meg Taylor
No edit summary
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{subpages}}
{{subpages}}
'''Aromatase inhibitors''', which inhibit the [[enzyme]] [[aromatase]] used biologically to produce estrogens, inhibit the biosynthetic production of [[estrogen]] [[steroid]]s.  Because of this action, these inhibitors are sometimes used to treat cancerous tumors which are estrogen-sensitive.  At present, three AIs are approved by the FDA<ref>[http://www.cancernet.gov/cancertopics/aromatase-inhibitors CancerNet]</ref> :
'''Aromatase inhibitors''', which inhibit the [[enzyme]] [[aromatase]] used biologically to produce estrogens, inhibit the biosynthetic production of [[estrogen]] [[steroid]]s.  Because of this action, these inhibitors are sometimes used to treat cancerous tumors, which are estrogen-sensitive, especially [[breast cancer]] in postmenopausal women.  At present, three AIs are approved by the FDA<ref>[http://www.cancernet.gov/cancertopics/aromatase-inhibitors CancerNet]</ref> :


* [[anastrazole]] (Arimidex®)  
* [[anastrazole]] (Arimidex®)  
Line 7: Line 7:


==References==
==References==
<references/>
{{reflist}}

Revision as of 03:15, 7 October 2013

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Aromatase inhibitors, which inhibit the enzyme aromatase used biologically to produce estrogens, inhibit the biosynthetic production of estrogen steroids. Because of this action, these inhibitors are sometimes used to treat cancerous tumors, which are estrogen-sensitive, especially breast cancer in postmenopausal women. At present, three AIs are approved by the FDA[1] :

References